Despite significant advances in therapy, the 5-year survival rates for patients with advanced stage oral cancers still remains poor as an appropriate treatment has not been found yet, due to side effects of chemo/radiotherapy. Verbascoside (VB), a major bioactive constituent of the Tsoong herb, displays pharmacological properties by exhibiting anti-oxidative, anti-inflammatory and anti-cancer activities. However, the underlining function and mechanism of VB in human oral squamous cell carcinoma (OSCC) remains unclear. In this study, we show that VB significantly decreased the viability and metastasis of HN4 and HN6 tumor cells, while promoting apoptosis. A xenograft OSCC mouse model further showed that intraperitoneal injection of VB strongly inhibited growth and lung metastasis of implanted tumor cells. Immunoblot analysis confirmed that VB effectively suppressed nuclear factor (NF)-jB activation and downstream Bcl-2/Bcl-XL expression, resulting in increased OSCC cell apoptosis. In addition, VB suppressed mRNA and protein expression of matrix metalloproteinase-9 via suppression of NF-jB activation, thereby inhibiting tumor cell metastasis. Inspiringly, compared to cisplatin-treated group, VB is a biocompatible agent without signficant side effects in vivo. Collectively, our results demonstrate that VB effectively inhibits OSCC tumor cell growth and metastasis via suppression of IjB kinase complex (IKK)/NF-jB-related signaling activation, suggesting that VB has potential use as a potent anticancer agent in OSCC therapeutic strategies.
Introduction
As the sixth most prevalent malignancy worldwide, oral cancer is a major global health issue. 1 The most common type of oral cancer, oral squamous cell carcinoma (OSCC), results from an accumulation of multiple genetic mutations that ultimately causes damage to oral epithelial cells. 2 OSCC remains the major cause of head and neck cancer-associated morbidity and mortality. OSCC requires multimodal treatment involving surgery, radiotherapy and chemotherapy. However, despite modern surgical techniques and therapeutic strategies, such as cisplatin (DDP), cetuximab and taxanes, OSCC mortality rates remain high in most countries, with an overall 5-year survival rate below 50%. 3 Low survival rates and significant toxicities of current treatment strategies highlight the need for new OSCC treatment options. Several studies suggest that the consumption of antioxidant-rich foods is associated with a lowered risk of developing some chronic illnesses. 4 Thus, there has been an increasing interest in antioxidants naturally present in fruits, vegetables, herbs and beverages. Verbascoside (VB) is a wellstudied phenylethanoid glycoside found in several plant species. A number of studies indicate that VB exhibits anti-oxidative, 5 anti-inflammatory, 6 anti-bacterial 7 and anti-fungal properties. 8 Moreover, VB has been shown to possess antitumor activity in the treatment of colorectal cancer, leukemia, gastric carcinoma and breast adenocarcinoma. 9 For example, VB increases colorectal cancer cell apoptosis by effectively activating the HIPK2-p53 signaling pathway. 10 Additionally, VB effectively inhibits the growth of K562 tumor cells and induces their apoptosis. 11 Along with inducing cellular apoptosis, VB has the capacity to act as a strong radical scavenger against tested radicals and is cytotoxic against HEP-2, RD and MCF-7 (human breast adenocarcinoma) cell lines. 12 While these studies are exciting and suggest VB as a potent anticancer agent, its underlying function and mechanism in OSCC remains unclear and requires further elucidation.
In our study, we analyzed the potential function and mechanism of VB in OSCC cells in vitro and in vivo. We demonstrated that VB plays an essential role in decreasing the viability, migration and invasion of HN4 and HN6 tumor cells, while promoting apoptosis. Using a xenograft OSCC mouse model, we tested the pro-apoptotic and antimetastatic effects of VB in vivo. To explore the possible mechanism by which VB exerts its anti-tumor effects in OSCC cells, we measured the protein levels of IjBa, nuclear factor (NF)-jB p65 and matrix metalloproteinase-9 (MMP-9), as well as apoptosis-related gene products, Bax and Bcl-2/ Bcl-XL, in HN4 and HN6 tumor tissues. We concluded that VB effectively inhibited OSCC tumor cell growth and metastasis via suppression of IjB kinase complex (IKK)/NF-jBrelated signaling activation. Furthermore, compared to DDPtreated mice, apparent organ injury and inflammation was not observed in high-dose VB-treated nude mice, indicating negligible histological toxicity of VB. Based on these findings, we concluded that hypotoxic VB has potential use as a potent anticancer agent in OSCC therapeutic strategies.
Materials and Methods

Cell culture
Human OSCC cell lines (HN4 and HN6) were kindly gifted by Professor Wantao Chen (Shanghai Jiaotong University). 13, 14 The Medical Ethics Committee of Nanjing Medical
University approved the application of these cell lines for this study. HN4 and HN6 cell lines were maintained in Dulbecco's modified Eagle's medium/F12 containing 10% fetal bovine serum (FBS) (Gibco, CA), penicillin (100 U/ml) and streptomycin (100 lg/ml) in a humidified incubator at 378C with 5% CO 2 .
Cell viability and proliferation assays
Cell viability and proliferation was assessed by conventional MTT reduction assay. 15 Briefly, HN4 or HN6 cells were seeded at a density of 2 3 10 5 cells/ml in a 96-well plate and allowed to adhere overnight. The cells were then treated with the indicated concentrations of VB (Santa Ana, CA) or DDP (Sigma-Aldrich, St. Louis, MO) for 24 hrs. After the exposure period, the cells were washed twice using serum-free medium and incubated with MTT solution (0.5 mg/ml; Sigma) for 4 hrs at 378C. The formazan precipitate was dissolved in dimethylsulfoxide (Sigma-Aldrich) and the absorbance at 490 or 570 nm was measured using a microplate reader (Perlong, Beijing, China). Each concentration was repeated three times.
AO/EB staining assay
HN4 or HN6 cells were incubated with the indicated concentrations of VB or 5 lM of DDP for 24 hrs. To stain apoptotic cells, the cells were trypsinized for 5 min before adding 1 ml of acridine orange (AO)/ethidium bromide (EB) dye mixture (100 mg/ml AO and 100 mg/ml EB, Sigma-Aldrich) to
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Flow cytometry analysis
HN4 or HN6 cells were cultured in six-well plates and exposed to the indicated concentrations of VB or 5 lM of DDP for 24 hrs. The cells were then digested with 0.25% trypsin and incubated with 20 ml binding buffer, 5 ml Annexin V-FITC and 5 ml propidium iodide (Invitrogen). After incubation in darkness at room temperature for 15 min, cells were analyzed by flow cytometry. 16 The results were calculated using CellQuest TM Pro software (BD Biosciences, San Jose, CA) and expressed as the percentage of apoptotic cells from the total number of cells.
Transwell migration and matrigel invasion assays
Cell migration and invasion were evaluated using a 24-well Millicell hanging cell culture insert (8.0 mm pore size; PIEP12R48) purchased from Millipore Corporation (Billerica, MA) with or without Matrigel (B&D Biosciences, San Jose, CA). After treatment with the indicated concentration of VB, or 5 lM DDP, HN4 or HN6 cells were starved overnight, suspended in serum-free medium, and placed in the upper chamber. The bottom chamber of the migration or invasion plate was filled with conditioned medium containing 10% FBS. After a 24-hr incubation period, a cotton swab was used to wipe and remove the cells from the upper chamber. Cells that migrated or passed through the filter were fixed with 100% ethanol and then stained for 30 min with 0.1% crystal violet. 17 Cells were observed with a light microscope and counted in five randomly selected fields. The average number of cells in each field was then calculated.
TUNEL assay
In vitro apoptosis assays were measured by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (In Situ Cell Death Detection Kit, TMR red; Roche Applied Science, Basel, Switzerland). HN6 cells were cultured on coverglass in 12-well plates. After 24-hr treatment, the apoptotic cells were stained with red fluorescence using the TUNEL reaction mixture as per the manufacturer's instructions. Hoechst dye was used to mark all cells with blue fluorescence. For quantitative results, the stained cells were examined under a fluorescence microscope and TUNEL-positive cells were counted in five random image areas for each sample using the Image J program. For in vivo apoptosis analysis, sections of HN4 or HN6 tumor tissues from nude mice were deparaffinized in xylene, rehydrated, washed with phosphate-buffered saline (PBS) and prepared for TUNEL assay as per the manufacturer's protocol. 18 Brown staining of nuclei, which were counted and compared to the control group, identified TUNEL-positive cells. Ten independent microscopic field-of-views were quantified manually for statistical comparisons.
Wound-healing assay
Cell migration was further detected by wound-healing assay. Briefly, HN6 cells were treated with 50 lM VB or 5 lM DDP for 24 hrs and cultured to about 90% confluence in a six-well plate. A wound was then created using a sterile 100 ll micropipette tip. Cell debris was washed away three times with PBS, and then 1 ml serum-free culture medium was added. The migrated cell count was determined at 24 hrs. The wound healing experiment was performed in triplicate.
Quantitative RT-PCR
Total RNA from cells was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA) and then reverse transcribed to cDNA in a total volume of 20 ml using a reverse transcription reaction kit (Promega Corporation, Madison, WI) as per the manufacturer's instructions. The primer sequences for MMP-9 were 5 0 -ACGCACGACGTCTTCCAGTA-3 0 (forward) and 5 0 -CCACCTGGTTCAACTCACTCC-3 0 (reverse). The primer sequences for GAPDH were 5 0 -CCTCGTCTCATAGACAAGA TGGT-3 0 (forward) and 5 0 -GGGTAGAGTCATACTGG AACATG-3 0 (reverse) (internal control). The level of MMP-9 gene transcript was measured by assessing the mRNA copy number related to 1 lg of total RNA using SYBR Green Reagent (Invitrogen) on an Applied Biosystems 7300 Sequence Detection system as per the manufacturer's instructions.
Western blotting
Whole-cell protein lysates were prepared and subjected to Western blotting as described previously. 19 Protein extracts were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. The membranes were then blocked with 5% skim milk in Tris-buffered saline with Tween solution (TBST, 50 mM Tris-HCl, PH 8.0, 150 mM NaCl, and 0.1% Tween-20) for 1 hr, and then incubated overnight at 48C in TBST with primary antibody, including rabbit anti-IjBa (1:1,000, Cell Signaling Technology), anti-NF-jB p65 (1:1,000, Cell Signaling Technology), anti-Histone H3 (1:1,000, Cell Signaling Technology), anti-Bcl-2 (1:1,000, Cell Signaling Technology), anti-Bcl-XL (1:1,000, Cell Signaling Technology), anti-Bax (1:1,000, Cell Signaling Technology), anti-MMP-9 (1:1,000, Cell Signaling Technology) and GAPDH (1:1,000, Cell Signaling Technology). Following incubation with horseradish peroxidase-conjugated IgG (1:2,000, Bioworld Biotechnology) for 1 hr, the antibodies were detected using an enhanced chemiluminescence (ECL) kit (PerkinElmer) and visualized with the ChemiDoc XRS system (Bio-Rad). Histone H3 and GAPDH were used as controls to verify equal protein loading.
Blood analysis and histological examination
Age-and weight-matched healthy female BALB/c mice were intraperitoneally (i.p.) injected with PBS (100 ll, blank negative control) or VB (100 ll, 80 mg/ml, n 5 6) every other day. As a positive control, nude mice were i.p. injected with DDP (5 mg/kg/mouse) twice a week. 20 The body weights of the mice were measured every other day. After 30 days, the mice were euthanized and approximately 500 ll blood samples were collected from each mouse, followed by blood chemistry tests and whole blood cell analyses. The organs were harvested, fixed in 4% buffered paraformaldehyde for 48-72 hrs, and then embedded, sliced and stained with hematoxylin and eosin (H&E) before being observed under an optical microscope (Leica).
Animals experiments
All animal experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care Committee of Nanjing Medical University (Nanjing, China). Four-to-six-week-old female BALB/c athymic nude mice were maintained in a sterile environment on a daily 12 hrs light/12 hrs dark cycle. Approximately 1-2 3 10 6 human HN4 or HN6 cells were subcutaneously injected into the flanks of the nude mice as described previously. 15 When the tumors became palpable at a size of 2 mm in diameter (about 1 week after implantation), mice were randomly divided into three groups, with six mice in each group. Mice bearing tumors were i.p. injected with DDP (5 mg/kg/mouse) twice a week 21 or VB (100 ll, 8 mg/ml) 22 every other day, and the tumor volumes of the mice were estimated using the formula: volume 5 (width) 2 3 length/2. Three weeks later, the primary tumors were carefully removed, imaged and analyzed via H&E staining, TUNEL staining, Western blotting and quantitative real-time polymerase chain reaction (RT-PCR).
For tumor cell metastasis assays, 1 3 10 6 HN4 or HN6 cells treated with blank control (PBS, 10 ll), VB (50 lM) or DDP (5 lM) were resuspended in PBS and injected into the tail vein of BALB/c nude mice. All mice were killed by 25 days after injection. The metastasis nodules in the lung tissues were stained with H&E. 19 In a separate experiment, the nude mice were intravenously (i.v.) injected with HN4 or HN6 cells treated with PBS, VB or DDP, and observed twice a week for survival experiments.
Statistical analysis
The GraphPad Prism 5 and SigmaPlot 11.0 packages were used. Data are presented as the means 6 standard error of the mean (SEM). Technical as well as biological triplicates of Cancer Therapy and Prevention each experiment were performed. Comparison between two groups was performed by Student's t test. Multiple-group comparisons were determined using one-way analysis of variance. A p < 0.05 was considered statistically significant.
Results
Role of VB in HN4 cell proliferation and apoptosis DDP, is a DNA damage-inducing chemotherapy drug that is widely used in the treatment of head and neck and oral malignancies. 23 As a positive control, we identified the functional concentration of DDP in HN4 cells. As shown in Figure 1a , MTT analysis clearly showed that DDP reduced cell viability in a dose-dependent manner. Based on these results, 5 lM DDP was selected for subsequent experiments to induce mild apoptosis. As a major bioactive constituent of the Tsoong herb, it has been demonstrated that VB can effectively promote apoptosis in human colorectal cancer 10 and other cancers. To further identify the function of VB in human oral squamous cell carcinoma, a dose-response analysis was performed in HN4 cells. To assess the effect of VB on HN4 cell activity, an MTT assay was performed. As depicted in Figure 1b , VB (50-200 lM) significantly reduced cell viability, which in line with 5 lM DDP-treated positive control. To test whether apoptosis was affected by VB, HN4 cells were further incubated with VB (0-200 lM) and DDP (5 lM) for 24 hrs and cell apoptosis was determined in an AO/EB assay. AO/EB dual staining uses the differential uptake of fluorescent DNA binding dyes, AO and EB, to distinguish viable cells (green), apoptotic cells (orange) and necrotic (dead) cells (red). 11 As shown in Figure 1c , similar to DDP-treated positive control, VB treatment led to an increase in the number of orangeand red-stained cells in a dose-dependent manner. Furthermore, a flow cytometry assay demonstrated that exposure to VB (50, 100 and 200 lM) markedly increased the apoptotic rate of cells (Figs. 1d and 1e) , which was consistent with the MTT and AO/EB assay results. Collectively, these results suggest that VB could decrease proliferation and induce apoptosis in HN4 cells.
Effect of VB on the migration and invasion of HN4 cells
To measure the effect of VB on tumor cell migration and invasion, a Transwell apparatus assay was used (Fig. 2) . HN4 cells, treated with VB (0-200 lM) and DDP (5 lM) for 24 hrs, were collected and cultured on a Transwell apparatus. Following a 24-hr incubation period, cell migration was 
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significantly decreased relative to the dose of VB and DDP (Figs. 2a and 2c) . Using a Transwell apparatus pre-coated with Matrigel, the effect of VB and DDP on cell invasiveness was examined after incubation for 24 hrs. As shown in Figures 2b and 2d , VB-treated cells demonstrated a significant decrease in invasiveness in a dose-dependent manner. As a control, cell invasiveness were strongly decreased in HN4 cells treated with DDP, which in line with previous studies. 21 Taken together, these results indicate that VB inhibits cell migration and invasion in HN4 cell lines. 50 lM VB was selected for subsequent experiments with the aim of inducing mild apoptosis and migration.
Effect of VB on the apoptosis, migration and invasion of HN6 cells
To further confirm the anti-OSCC function of VB, human HN6 cells were used as the recipient cells. HN6 cells were incubated with 50 lM VB and 5 lM DDP for 24 hrs and the level of apoptosis was detected by AO/EB assay, flow cytometry assay and TUNEL staining. In agreement with above results, HN6 cells treated with VB exhibited changes characteristic of apoptosis, for example, formation of apoptotic bodies (Fig. 3a, red arrow indicated) . Moreover, flow cytometry analysis clearly showed that after incubation with VB and DDP for 24 hrs, the apoptotic rate of HN6 cells increased nearly fourfold (VB-treated group) and fivefold (DDP-treated group) when compared to cells treated with a PBS control (blank group), however, there is no statistical difference between VB-and DDP-treated group (Figs. 3b and  3c ). In addition, we observed a similar induction effect of VB on apoptosis using TUNEL assay in HN6 cells (Figs. 3d and  3e) . Furthermore, the migration capacity of HN6 cells was assessed using a wound healing assay and a Boyden chamber coated with Matrigel. As depicted in Figure 3f , VB treatment significantly inhibited the migration of HN6 cells. Moreover, compared to the blank control, HN6 cell migration (Figs. 3g and 3h) and invasion (Figs. 3g and 3i) across Transwell filters were also strongly inhibited by VB. These results show that VB promotes apoptosis in HN6 cells, while inhibiting migration and invasion, suggesting that VB may have the capacity to alter OSCC tumor cell function.
Effect of VB on HN4 and HN6 tumor growth and metastasis
We next tested whether administration of VB can effectively suppress implanted tumor growth and metastasis in BALB/c athymic nude mice. In this experiment, 4-to-6-week-old female mice were subcutaneously implanted with 1-2 3 10 6 HN4 or HN6 cells. Seven days post-implantation, mice were randomly divided into three groups, with six mice in each group. Mice were i.p. injected with PBS (blank group, 100 ll) or VB (100 ll, 8 mg/ml/mouse) every other day, or DDP (5 mg/kg/mouse) twice a week. As shown in Figure 4 , treatment with VB or DDP effectively reduced the size (Fig.  4a) , volume (Figs. 4b and 4c) and dry weight (Figs. 4d and 4e) of the implanted HN4 or HN6 tumors compared to the PBS-treated negative control. Next, we tested the metastasis of tumor cells to the mouse lung and the survival of tumorbearing mice. In this experiment, BALB/c nude mice from each group were sacrificed approximately 25 days after tail vein injection of HN4 or HN6 cells treated with blank control (PBS, 10 ll), VB (50 lM) or DDP (5 lM) to determine lung metastasis. The lung specimens of these mice were insufflated, fixed and stained with hematoxylin to identify tumor masses within the lungs (Fig. 4f , black arrow indicated). As expected, VB or DDP treatment markedly reduced the number of lung metastases compared to the blank control 
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group (Figs. 4g and 4h) . Furthermore, after treatment with VB or DDP, tumor-bearing mice displayed a notably longer survival course (Figs. 4i and 4j) . Importantly, we further tested the apoptosis of the tumor tissue of tumor-bearing mice. The tumor specimens of these mice were insufflated, fixed and stained with hematoxylin and TUNEL to identify apoptotic masses within the tumors. As expected, VB or DDP treatment markedly induced the apoptosis of the tumor cells in comparison to the blank control group (Figs. 4k and  4l) . Although DDP-treated control was still slightly more potent apoptosis, the difference between VB and DDP used did not seem to be significant (Fig. 4l) . Collectively, these data strongly suggest that VB effectively suppresses not only oral tumor cell growth but also oral tumor cell metastasis to the lungs.
Effect of VB on NF-jB activation in HN4 and HN6 tumors VB has been described in the literature to possess a wide array of biological properties, including antioxidant, antiinflammatory and chelating activity. 24, 25 Furthermore, the nuclear IKK/NF-jB signaling pathway has been well characterized and is known to mediate apoptosis 26 and migration. 27 We evaluated the possibility that VB affected apoptosis and migration in HN cells by mediating NF-jB activation by analyzing the cytoplasmic levels of IjBa and nuclear levels of NF-jB in HN4 and HN6 tumor tissues. As shown in Figures 5a and 5c , VB or DDP strongly increased the basal level of IjBa in HN4 (Fig. 5a ) and HN6 tumors (Fig. 5c ). In agreement with this finding, Figures 5b and 5d showed that treatment by VB or DDP significantly decreased the basal level of nuclear NF-jB p65 in HN4 (Fig. 5B ) and HN6 tumors (Fig. 5d) . These results collectively suggest that VB induces the expression of IjBa and consequently reduces the activation of NF-jB in treated tumor tissues.
Bcl-2/bcl-XL/bax and MMP-9 expression in VB-treated HN4 and HN6 tumors Bcl-2/Bcl-XL can be regulated by NF-jB in some cells, 28 thus, we postulated that the reduction in NF-jB activation due to VB or DDP treatment may also down-regulate Bcl-2/ Bcl-XL expression. As shown in Figures 6a and 6d , Bcl-2 and Bcl-XL expression decreased with evident increases in Bax expression in HN4 (Fig. 6a) and HN6 tumor tissues (Fig. 6d) treated with VB or DDP. Interestingly, we further found that VB or DDP markedly suppressed MMP-9 expression via blocking the activation of the NF-jB pathway in VB-treated HN4 (Figs. 6b and 6c) and HN6 (Figs. 6e and 6f) tumor tissues. Combined with the aforementioned results, these data indicate that VB reduces the expression of Bcl-2/Bcl-XL and MMP-9 and upregulates the level of Bax, most likely due to decreased NF-jB activation.
Biocompatibility of VB in vivo
To assess the biocompatibility of VB in vivo, high-dose VB (100 ll, 80 mg/ml) 29 was i.p. injected into mice every other day. As a positive control, nude mice were i.p. injected with DDP (5 mg/kg/mouse) twice a week. 20 The body weights of the mice were measured every other day. We found that the body weights of the mice from VB-treated groups did not differ significantly from those of the blank control group. However, DDP-treated mice observed a marked reduction in body weight compared to the blank control group (Fig. 7a) . Thirty days after injection, the mice were euthanized for blood biochemistry and hematology analyses, as well as histological examinations. Sex-, age-and weight-matched healthy mice treated with PBS were used as controls. Compared with the DDP treatment group, indicators of liver (Figs. 7b and 7c) and kidney (Figs. 7d and 7e ) function did not change significantly, suggesting that intraperitoneal injection of VB did not lead to reductions in hepatic or renal function. In addition, the heart, liver, spleen, lungs and kidneys were harvested for H&E staining. Apparent organ injury and inflammation was not observed compared to the DDP 
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control group (Fig. 7f, asterisk indicated) , indicating VB's negligible histological toxicity. These results demonstrate that VB is a biocompatible agent without significant side effects in vivo.
Discussion
OSCC is a solid tumor of epithelial origin that affects >400,000 individuals annually worldwide. 30 Definitive concurrent chemoradiotherapy is considered standard of care for inoperable locoregionally advanced OSCC. 31 DDP is the most common chemotherapeutic agent used in combination with radiotherapy in the treatment of OSCC. 32 However, DDP has severe side effects such as nephrotoxicity. 33 Therefore, the development of new therapeutic methods of high curative value as well as low toxicity and side effects, especially for patients with advanced OSCC, is needed.
Accumulating evidence suggests that VB, a phenylethanoid glycoside, may be used as a potential anti-cancer agent. 34 However, the underlying function and mechanism in OSCC remains unclear. In our study, we demonstrated that VB effectively decreased the viability, migration and invasion of implanted OSCC cells and promoted the apoptosis of tumor cells by inhibiting NF-jB activation and protein expression downstream in its signaling pathway. Our data concur with previous reports of the therapeutic potential of VB in cancer treatment.
Previously, numerous studies have shown that VB effectively increases cancer cell apoptosis. For instance, VB promotes apoptosis by activating the HIPK2-p53 signaling pathway in colorectal cancer cells, 10 exerts a tumorsuppressive function by inducing apoptosis in human immortalized myelogenous leukemia 15 and suppresses tumorigenicity through pro-apoptosis in hepatocellular carcinoma cells. 5 However, the literature on VB's anticancer activity toward different tumor types has not been sufficiently considered. 10, 11, 35 Our results further demonstrated that VB inhibited cell growth and promoted cell apoptosis in OSCC in vitro and in vivo. In our work, we observed a decrease in survival and an increase in apoptosis in HN4 (Fig. 1) and HN6 (Fig. 3 ) OCSS cells treated with various concentrations of VB. This finding was similar to observations made by Zhou et al. in HCT-116, LoVo, HT-29 and SW62 cells. 10 Furthermore, we tested the anti-tumor activity of VB in an in vivo mouse model of human OCSS and found that VB significantly inhibited xenograft tumor growth. H&E staining and TUNEL staining analyses also showed heightened levels of apoptotic cells in VB-treated tumor tissues. In investigating the mechanism by which VB promotes apoptosis, we first learned that, in both OSCC cells and tumors, VB effectively inhibited the degradation of IjBa and decreased the basal level of nuclear NF-jB p65 protein (Fig.  5) . This supports the previous finding through mutational analysis of the promoter that a major target of VB is the NFjB pathway. 4 As a downstream regulator of NF-jB, anti-apoptotic Bcl-2/Bcl-XL protein expression was reduced, whereas the level of pro-apoptotic Bax protein was greatly boosted in HN4 (Fig. 6a) and HN6 (Fig. 6d) tumors after VB treatment. These results imply that VB promotes OSCC cell apoptosis through IKK/NF-jB-related signaling.
Cancer recurrence and death in cancer patients are mostly due to invasion and metastasis of tumor cells. 36 Thus, we next evaluated the inhibitory effect of VB on invasion and migration in HN4 and HN6 cells. Our data showed that VB inhibited HN4 cell invasion in a dose-dependent manner (Fig. 2) . Also, treatment with 50 lM VB inhibited HN6 cell invasion and migration in a similar manner (Figs. 3f-3I ). Importantly, VB markedly inhibited HN4 (Figs. 4f and 4g ) and HN6 (Figs. 4f and 4h) tumor cell metastasis to the lungs in vivo. Although the anti-tumor activity of VB is widely accepted, the precise mechanism of its anti-metastatic potential in OSCC cells is unclear. MMPs play an important role in tumor invasion, angiogenesis, inflammatory tissue destruction and cancer cell metastasis. 4, 37 Among the human MMPs reported to date, MMP-2 and 29, which are expressed abundantly in various malignant tumors, contribute to cancer invasion and metastasis. 4, 38 Intriguingly, NF-jB has also been found to regulate the expression of MMPs, especially the expression of MMP-9, which degrades and reshapes the extracellular matrix to enhance invasion of tumor cells. 36 We, therefore, sought to determine the effect of VB on MMP-9 expression. Our results showed that VB significantly suppressed NF-jB activation (Fig. 5) and further inhibited expression of MMP-9 in VB-treated HN4 (Figs. 6b and 6c ) and HN6 (Figs. 6e and 6f) tumor tissues. This finding makes sense since previous studies show that NF-jB regulates MMP-9, as the MMP-9 gene promoter contains NF-jB binding sites. 39 These results suggest that VB reduces OSCC tumor cell metastasis through inhibiting NF-jB activation and subsequently decreasing MMP-9 expression. Previous studies demonstrated that VB could decrease tyrosinase activity and melanin biosynthesis in B16F10 cells by activating ERK signaling, which down-regulated microphthalmia-associated transcription factor, tyrosinase and tyrosinase-related protein-1 production. 40 VB also inhibited phorbol-12-myristate-13-acetate (PMA)-induced invasion and migration of human fibrosarcoma cells via Ca (21) -dependent CaMK/ ERK and JNK/NF-jB-signaling pathways. 4 Thus, VB may also involve modulation of other signaling pathway, such as ERK or JNK/NF-jB signaling, to inhibit metastasis in human OSCC, which is necessary to clarify the details in future research.
Although chemically synthesized chemotherapeutic agents demonstrate activity in a metastatic cancer setting, some of these chemotherapy drugs have undesirable toxic side effects. 41, 42 For example, DDP is an essential chemotherapeutic agent used to treat OSCC clinically, however, its use as either a single agent or in combination with other drugs induces specific toxicities, notably, neurotoxicity and nephrotoxicity. Paclitaxel (PTX), a highly hydrophobic diterpenoid, is also one of the most widely used anti-cancer drug for treating various tumors, such as OSCC, prostate, breast, ovarian, lung, bladder, liver and others. 43 However, compared to DDP, the disadvantages of PTX have hampered its clinical applications, which include poor water solubility (<0.03 mg/ ml aqueous solubility) and low oral bioavailability. 44 Therefore, DDP was chosen as a positive control group. The nontoxic effect of VB is of particular interest. We assessed the biocompatibility of VB in vivo. Our data suggest that, compared to the DDP-treated control group, injection of highdose VB did not lead to reductions in hepatic (Figs. 7b and 7c) or renal (Figs. 7d and 7e) functions. In addition, apparent organ injury and inflammatory changes were not observed when compared to the DDP treatment control group (Fig.  7f) , indicating that VB has negligible histological toxicity. These results demonstrate that VB is a biocompatible agent without significant side effects in vivo.
In conclusion, our study first demonstrated that low toxicity of VB exerted pro-apoptotic and anti-metastatic potential in OSCC HN4 and HN6 cells. We further investigated the mechanism of these effects and demonstrated that: (i) VB inhibited Bcl-2/Bcl-XL expression and promoted Bax expression by reducing NF-jB nuclear levels, resulting in the inactivation of the nuclear IKK/NF-jB signaling pathway and increased cell apoptosis and (ii) VB suppressed HN cancer cell migration and invasion by inhibiting MMP-9 expression through the NF-jB signaling pathway. Collectively, the results of our study provide a scope for developing VB as a therapeutic agent for treating OSCC and for other pharmacological applications.
